Compare Microsoft (MSFT) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microsoft vs TG Therapeutics Inc — how do they compare? Microsoft trades at $396.1 (market cap $2.99T), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: Microsoft is far larger — about 362× TG Therapeutics Inc's market cap, and Microsoft pays a 0.9% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MSFT | TGTX | |
|---|---|---|
Market Cap | $2.99T | $8.26B |
Volume | 36,654,621 | — |
Sector | Technology | Health |
52-Week High | $542.07 | $59.06 |
52-Week Low | $352.83 | $26.39 |
Enterprise Value | $2.97T | $8.50B |
Dividend Yield | 0.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microsoft trades at $397.75, up 1.0% with strong technical momentum as price approaches pivot point resistance at $398. The company demonstrates robust fundamentals with Q1 2026 EPS beating expectations at $4.27 versus $4.06, continuing a trend of earnings outperformance. Revenue growth accelerated to $281.72B in 2025 with net income margins expanding to 36.14%. Recent news highlights Microsoft's AI leadership through Azure and Copilot initiatives, though concerns about capital expenditures persist.
Microsoft presents a compelling investment case with 80% analyst buy ratings and a $546.70 consensus price target representing 37% upside. The company's AI positioning and cloud dominance support long-term growth, but risks include competitive pressures, high valuation multiples (P/E 23.96), and market volatility. Strong cash flow generation ($136.16B operating cash flow) and consistent dividend payments provide shareholder stability amid growth investments.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
